Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03CUF
|
|||
Former ID |
DAP000993
|
|||
Drug Name |
Furazolidone
|
|||
Synonyms |
Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diarrhea [ICD-11: ME05.1; ICD-9: 787.91] | Approved | [1] | |
Therapeutic Class |
Antiinfective Agents
|
|||
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C8H7N3O5
|
|||
Canonical SMILES |
C1COC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]
|
|||
InChI |
1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
|
|||
InChIKey |
PLHJDBGFXBMTGZ-WEVVVXLNSA-N
|
|||
CAS Number |
CAS 67-45-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
10200, 72440, 602746, 7847895, 8000339, 8139923, 8149352, 10532427, 11058827, 15220531, 24870024, 24894997, 26611752, 26679646, 26749310, 29215179, 39296723, 47275491, 47424181, 47646502, 48018845, 48094488, 48243304, 48393877, 49699022, 49747527, 50001677, 50085998, 50107562, 50107563, 52074133, 53786873, 57361168, 57650761, 58025007, 81040775, 81093031, 85240169, 85787354, 85789182, 88484924, 92124226, 92307333, 92711038, 93166340, 99301173, 103304486, 106225507, 114181310, 124526348
|
|||
ChEBI ID |
CHEBI:5195
|
|||
SuperDrug ATC ID |
G01AX06
|
|||
SuperDrug CAS ID |
cas=000067458
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides caccae was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Furazolidone (adjusted p-values: 6.13E-06). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Furazolidone (adjusted p-values: 5.73E-06). | |||
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides ovatus was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides thetaiotaomicron was decreased by Furazolidone (adjusted p-values: 9.93E-06). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Furazolidone (adjusted p-values: 1.44E-06). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Furazolidone (adjusted p-values: 2.04E-06). | |||
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides xylanisolvens was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Furazolidone (adjusted p-values: 4.82E-07). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Furazolidone (adjusted p-values: 4.93E-07). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Furazolidone (adjusted p-values: 4.33E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium adolescentis was decreased by Furazolidone (adjusted p-values: 5.17E-06). | |||
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium longum was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Furazolidone (adjusted p-values: 2.73E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eggerthella lenta was decreased by Furazolidone (adjusted p-values: 5.37E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli ED1a was decreased by Furazolidone (adjusted p-values: 5.15E-06). | |||
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli IAI1 was decreased by Furazolidone (adjusted p-values: 4.93E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Erysipelatoclostridium ramosum was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Blautia obeum was decreased by Furazolidone (adjusted p-values: 7.48E-07). | |||
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridioides difficile was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridium perfringens was decreased by Furazolidone (adjusted p-values: 1.33E-06). | |||
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Coprococcus comes was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Dorea formicigenerans was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Enterocloster bolteae was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium eligens was decreased by Furazolidone (adjusted p-values: 7.00E-06). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Furazolidone (adjusted p-values: 1.63E-04). | |||
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lacrimispora saccharolytica was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia hominis was decreased by Furazolidone (adjusted p-values: 1.66E-05). | |||
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia intestinalis was decreased by Furazolidone (adjusted p-values: 2.39E-04). | |||
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus bromii was decreased by Furazolidone (adjusted p-values: 1.78E-05). | |||
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus gnavus was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus torques was decreased by Furazolidone (adjusted p-values: 1.74E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Furazolidone (adjusted p-values: 1.45E-05). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Furazolidone (adjusted p-values: 9.95E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Veillonella parvula was decreased by Furazolidone (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Akkermansia muciniphila was decreased by Furazolidone (adjusted p-values: 4.62E-06). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial Deoxyribonucleic acid (Bact DNA) | Target Info | Modulator | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011270. | |||
REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 3 | Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.